Differential Clinical Impact of Letermovir Prophylaxis According to Graft Sources: a KSGCT Multicenter Retrospective Analysis

Takashi Toya,Kota Mizuno,Masatoshi Sakurai,Jun Kato,Takehiko Mori,Noriko Doki,Shinichi Masuda,Nobuyuki Aotsuka,Shokichi Tsukamoto,Emiko Sakaida,Yuki Nakajima,Shin Fujisawa,Shinichiro Machida,Yasuyuki Aoyama, Hiroki Yokoyama,Katsuhiro Shono,Yoshihiro Hatta,Kensuke Usuki,Keisuke Kataoka,Kazuteru Ohashi

Blood Advances（2023）

引用 0|浏览6

暂无评分

摘要

•Letermovir prophylaxis after HSCT suppressed clinically significant CMV infection regardless of graft sources.•Impact of letermovir prophylaxis on non-relapse mortality was remarkable in BMT/PBSCT rather than in CBT.

查看译文

关键词

letermovir,cytomegalovirus,allogeneic stem cell transplantation,graft source

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要